AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the U.S. and Canada) today announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, Lynparza (olaparib).
Resultat publicerade i The Lancet Diabetes & Endocrinology från observationsstudien CVD-REAL Nordic, baserad på svenska registerdata, indikerar att behandling av typ 2-diabetes med SGLT-2-hämmare i klinisk praxis är associerad med minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.
AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for acalabrutinib, a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor.
AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib .
Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three years.
AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (osimertinib) compared to current 1st-line standard-of-care treatment......
AstraZeneca and MedImmune today announced progression-free survival (PFS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab versus platinum-based standard-of-care (SoC) chemotherapy in previously-untreated patients with metastatic (Stage IV) 1st-line non-small cell lung cancer
AstraZeneca and Merck & Co., Inc., today announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
Pascal Soriot, koncernchef, kommenterar resultatet:
”Vårt resultat för första halvåret var i linje med förväntningarna eftersom vi påverkades av effekterna av patentutgången för Crestor och Seroquel XR i USA. Vi fortsatte att leverera nyskapande forskning inom alla våra forskningsområden, i synnerhet inom onkologi. Imfinzi lanserades mot cancer i urinblåsan, samtidigt som vi publicerade banbryt
AstraZeneca today announced that the European Commission (EC) has approved Faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
Måndag 31 juli öppnas portarna till årets upplaga av AstraZenecas sommarforskarskola och de kommande två veckorna kommer 52 elever i åldrarna 14–17 år få testa på inspirerande och lärorika experiment i laboratoriesalarna på Göteborgs universitet.
Kyntheum is the first and only fully-human monoclonal antibody that selectively targets the IL-17 receptor subunit A on skin cells.
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of Faslodex.
Måndag 19 juni öppnas portarna till årets upplaga av AstraZenecas sommarforskarskola och de kommande två veckorna kommer 52 elever i åldrarna 14–17 år få testa på inspirerande och lärorika experiment i laboratoriesalarna på KTH i Stockholm.
Resultat från den nordiska delen av observationsstudien CVD-REAL, presenterades vid ADA, den 11 juni. Resultaten visar att behandling av typ 2-diabetes med SGLT2-hämmare i klinisk verklighet är associerad med en signifikant minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.
Comprehensive updated analysis provides valuable evidence on the safety profile of Farxiga, including no imbalance in lower-limb amputations New analyses from CVD-REAL examine reductions in CV events for SGLT-2 inhibitors, including Farxiga in patients with and without CV disease versus DPP-4 inhibitors
AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon(exenatide extended-release), with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA, 9-13 June 2017
AstraZeneca today announced that it has entered an agreement with Grünenthal for the global rights to Zomig(zolmitriptan) outside Japan
AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with Lynparza (olaparib) tablets (300mg twice daily), compared to treatment with physician’s choiceof a standard of care chemotherapy.
AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.